Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 5Withdrawn 3Terminated 3

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Other solid neoplasm 1Head & Neck 1CNS 1

Conditions

Colorectal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × futuximab × Clear all
NCT02540161 2020-08-05

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

Duke University

Phase 2 Completed
43 enrolled 14 charts
CNS

Glioblastoma, Glioma

NCT02083653 2019-04-16

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Symphogen A/S

Phase 2 Completed
254 enrolled 21 charts
Gastrointestinal

Colorectal Neoplasms

NCT01117428 2018-10-15

Sym004 in Patients With Advanced Solid Tumors

Symphogen A/S

Phase 1/2 Completed
111 enrolled 18 charts
Gastrointestinal

Colorectal Neoplasms

NCT01417936 2018-10-15

Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy

Symphogen A/S

Phase 2 Completed
26 enrolled 20 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01955473 2017-08-23

Japanese Phase 1 Trial of Sym004 in Solid Tumors

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
51 enrolled 49 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡